Replies to post #89963 on NanoViricides Inc (NNVC)

[changes_iv]

No, no special information other than the following PR, among other positive PRs we've read in recent past:

December 9, 2013...

The Company’s drug development programs continue to progress satisfactorily. The broad-spectrum injectable FluCide™ anti-influenza drug is our most advanced drug candidate. Recently, the Company has announced that FluCide was found to be safe and well tolerated in a small non-GLP safety-toxicology study, even at the maximum feasible dosage level. In addition, the Company has successfully performed studies on the scale up of synthesis of FluCide.

source: http://www.nanoviricides.com/press%20releases/2013/NanoViricides%20Announces%20that%20its%20Annual%20Meeting%20was%20held%20on%20December%209th,%202013%20the%20CEO%20Presentation%20is%20available%20on%20the%20Redesigned%20Website.html